Evidence map›Paper›PMID 30559133›Full record

ArticleAntimicrobial agents and chemotherapy2019

Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda.

Victor Asua, Joanna Vinden, Melissa D Conrad, Jennifer Legac, Simon P Kigozi, Moses R Kamya, Grant Dorsey, Samuel L Nsobya, Philip J Rosenthal

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 3 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Malaria: past, present, and future.Signal transduction and targeted therapy · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. A retrospective analysis ofAntimicrobial agents and chemotherapy · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Victor AsuaInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0002-0489-4692
Joanna VindenSchool of Public Health Division of Infectious Disease and Vaccinology, University of California, Berkeley, Berkeley, California, USA.
Melissa D ConradDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Jennifer LegacDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Simon P KigoziInfectious Diseases Research Collaboration, Kampala, Uganda.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Grant DorseyDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Samuel L NsobyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA philip.rosenthal@ucsf.edu.
University of California, San Francisco · USInfectious Diseases Research Collaboration · UGLondon School of Hygiene & Tropical Medicine · GBUniversity of California, Berkeley · US

Funding

Transmission ProjectU19AI089674 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2010 to 2026
$29.3M
Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
Resistance of Malaria Parasites to Artemisinin-Based Combination TherapiesR56AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2008 to 2008
$618k
NIAID NIH HHS R01 AI075045NIAID NIH HHS R56 AI075045NIAID NIH HHS U19 AI089674
6 · The paper itself

Abstract

The potential spread of antimalarial drug resistance to Africa, in particular for artemisinins and key partner drugs, is a major concern. We surveyed

Indexed as

AntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsAspartic Acid EndopeptidasesATP-Binding Cassette, Sub-Family C ProteinsChildChloroquineDrug ResistanceFolic Acid AntagonistsHumansLumefantrineMalaria, FalciparumMembrane Transport ProteinsPiperazinesPlasmodium falciparumPolymorphism, Single NucleotideAntimalarialsArtemether, Lumefantrine Drug CombinationartemisininArtemisininsAspartic Acid EndopeptidasesATP-Binding Cassette, Sub-Family C ProteinsChloroquineFolic Acid AntagonistsLumefantrineMdr1 protein, Plasmodium falciparumMembrane Transport ProteinspiperaquinePiperazinesplasmepsin IIProtozoan ProteinsQuinolinesantimalarial drug sensitivitymolecular markersUganda

Identifiers

PMID30559133
PMCPMC6395896
OpenAlexW2904025006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.